In this tutorial you will find:
- How MilliporeSigma’s Single Molecule Counting (SMC™) platform can be used to detect even very low levels of Huntingtin protein
- How to reach fM levels of sensitivity detecting both mHTT and total HTT
- Development and validation of High Sensitivity SMC™ Immunoassays
It is known that Huntington’s Disease (HD) is caused by the expression of a mutated form of the Huntingtin protein containing a polyglutamine (polyQ) repeat, with the length of the repeat correlating to increased severity of the disease. Since concentrations of total and mutant HTT in premanifest and controls groups are extremely low, it is imperative the assays are able to reach fM levels of sensitivity. Employing the SMC™ technology we are able to provide the HD community with tools to enable better understanding of the disease and to assist in the development of new therapeutics. During this webinar we will review data from the development and validation of the High Sensitivity SMC™ Immunoassays for the Quantification of mHTT and total HTT.